KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $72.3 million.

  • West Pharmaceutical Services' Shares Outstanding (Weighted Average) fell 109.44% to $72.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.3 million, marking a year-over-year decrease of 109.44%. This contributed to the annual value of $73.0 million for FY2024, which is 174.97% down from last year.
  • West Pharmaceutical Services' Shares Outstanding (Weighted Average) amounted to $72.3 million in Q3 2025, which was down 109.44% from $72.3 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Shares Outstanding (Weighted Average) registered a high of $74.5 million during Q1 2023, and its lowest value of $72.3 million during Q2 2025.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $74.1 million (2021), whereas its average is $73.8 million.
  • In the last 5 years, West Pharmaceutical Services' Shares Outstanding (Weighted Average) soared by 67.66% in 2021 and then plummeted by 174.97% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Shares Outstanding (Weighted Average) (Quarter) stood at $74.4 million in 2021, then changed by 0.0% to $74.4 million in 2022, then dropped by 0.13% to $74.3 million in 2023, then fell by 1.75% to $73.0 million in 2024, then decreased by 0.96% to $72.3 million in 2025.
  • Its last three reported values are $72.3 million in Q3 2025, $72.3 million for Q2 2025, and $72.5 million during Q1 2025.